Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sevelamer, FGF-23 and Endothelial Dysfunction in CKD

NCT01135615 is registered in ClinicalTrials.gov with Gulhane School of Medicine as lead sponsor.

NCT NCT01135615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01135615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sevelamer, FGF-23 and Endothelial Dysfunction in CKD
Lead sponsor
Gulhane School of Medicine
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2008
Completion date
May 31, 2010
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

we investigated the relationship between plasma fgf23 levels and endothelial dysfunction in a sizable series of incident stage 3-4 ckd patients.